Theravance Biopharma, Inc.

Equities

TBPH

KYG8807B1068

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
8.97 USD -0.44% Intraday chart for Theravance Biopharma, Inc. +0.11% -20.20%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tranche Update on Theravance Biopharma, Inc.'s Equity Buyback Plan announced on September 19, 2022. CI
Transcript : Theravance Biopharma, Inc., Q4 2023 Earnings Call, Feb 26, 2024
Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q4 Revenue $17.6M, vs. Street Est of $17.6M MT
Theravance Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Theravance Biopharma Shares Drop Pre-Bell as Phase 4 Study of Lung Disease Treatment Fails to Meet Primary Endpoint MT
Top Premarket Decliners MT
Theravance Biopharma Announces Results from the Phase 4 YUPELRI®? PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease CI
Theravance Biopharma, Inc.'s Equity Buyback announced on September 19, 2022, has closed. CI
Theravance Biopharma Announces Appointment of Jeremy Grant to Board of Directors CI
Theravance Biopharma, Inc. Appoints Jeremy Grant as Independent Director CI
Viatris, Theravance Biopharma Say Trial in China Shows Efficacy, Safety of COPD Treatment MT
Transcript : Theravance Biopharma, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Tranche Update on Theravance Biopharma, Inc.'s Equity Buyback Plan announced on September 19, 2022. CI
Earnings Flash (TBPH) THERAVANCE BIOPHARMA US Reports Q3 Revenue $15.7M, vs. Street Est of $15.1M MT
Theravance Biopharma, Inc. Announces Board Changes CI
Theravance Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Theravance Biopharma, Mylan Reach Settlement Over Inhalation Drug Yupelri DJ
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders CI
Transcript : Theravance Biopharma, Inc., Q2 2023 Earnings Call, Aug 07, 2023
Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q2 Revenue $13.7M, vs. Street Est of $15.4M MT
Tranche Update on Theravance Biopharma, Inc.'s Equity Buyback Plan announced on September 19, 2022. CI
Theravance Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Theravance Biopharma, Inc.(NasdaqGM:TBPH) added to Russell 2000 Value-Defensive Index CI
Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell 3000E Growth Index CI
Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell 3000 Growth Index CI
Chart Theravance Biopharma, Inc.
More charts
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath and others. Its pipeline of internally discovered programs is targeted to address unmet patient needs. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. Its Selective 5-HT4 Agonist (TD-8954) is a selective 5-HT4 receptor agonist, which is developed for the treatment of gastrointestinal motility disorders.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
8.97 USD
Average target price
14 USD
Spread / Average Target
+56.08%
Consensus
  1. Stock
  2. Equities
  3. Stock Theravance Biopharma, Inc. - Nasdaq
  4. News Theravance Biopharma, Inc.
  5. Theravance Biopharma : Baird Adjusts Theravance Biopharma PT to $7 From $10, Maintains Neutral Rating